甲癌患者131I治疗出院标准及时间研究进展

摘要/Abstract

摘要： ¹³¹I治疗是分化型甲状腺癌患者术后安全、有效、重要的辅助治疗方式,同时有可能产生辐射危害。为了减少其辐射危害,甲状腺癌患者行大剂量¹³¹I治疗后需住院隔离治疗,其体内放射性活度、周围当量剂量率的高低等因素决定了患者需住院隔离时间的长短。本文介绍甲状腺癌患者¹³¹I治疗后出院标准、体内活度估算、辐射剂量的监测、住院隔离时间以及其预测因素等研究进展,为临床工作中实施规范、合理的出院标准以及进一步开展相关研究提供参考。

关键词: ¹³¹I, 分化型甲状腺癌, 出院标准, 出院时间

Abstract: ¹³¹I treatment is a safe, effective and important adjuvant way for patients with differentiated thyroid cancer, and it may cause radiation damage. In order to reduce the radiation hazard, patients need to be hospitalized after treatment with large doses of ¹³¹I. The length of time that patients need to be hospitalized is determined by the in vivo radioactivity, the surrounding equivalent dose rate, and so on. The progress of discharge criteria, in vivo activity estimation, radiation dose monitoring, hospitalization isolation time and it’s predictive factors after ¹³¹I treatment in patients with thyroid cancer, is summarized. It’s expected to provides reference for the implementation of standardized and reasonable discharge standards in clinical work, and further research.

Key words: Iodine-131, Differentiated thyroid carcinoma, Discharge criteria, Discharge time

中图分类号:

R818.05

易于颦, 胡凤琼. 甲癌患者¹³¹I治疗出院标准及时间研究进展[J]. 辐射防护通讯, 2019, 39(2): 43-48.

Yi Yupin, Hu Fengqiong. Progress in Discharge Criteria & Time for ¹³¹I treatment of Thyroid Cancer Patients[J]. RADIATION PROTECTION BULLETIN, 2019, 39(2): 43-48.

参考文献 44

[1]	Bann D V,Goyal N,Camacho F,et al. Increasing incidence of thyroid cancer in the Commonwealth of Pennsylvania[J]. JAMA, 2014,140(12):1149-1156.
[2]	Lim H, Devesa S S, Sosa J A, et al. Trends in thyroid cancer incidence and mortality in the United States,1974-2013[J]. JAMA,2017,317(13):1338.
[3]	Stewart B, Wild C. World cancer report 2014[M]. International Agency for Research on Cancer, 2014.
[4]	Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. Ca A Cancer Journal for Clinicians, 2016,66(2):115.
[5]	林岩松,李娇. 2015年美国甲状腺学会《成人甲状腺结节与分化型甲状腺癌诊治指南》解读:分化型甲状腺癌(131)I治疗新进展[J]. 中国癌症杂志, 2016,(01):1-12.
[6]	Blumhardt R, Wolin E A, Phillips W T, et al. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review[J]. Endocrine-related Cancer, 2014,21(6):473-84.
[7]	IAEA. IAEA Safety standards for protecting people and the environment[OL]. https://www-ns.iaea.org/standards/default.asp?s=11&l=90&w=1,2016-09-26/2018-03-12
[8]	IAEA. Radiation Protection and Safety of Radiation Sources: International Basic Safety Standards for Protection against Ionizing Radiation[R]. IAEA Safety standards Series No. GSR Part 3, 2014.
[9]	ICRP. Release of patients after therapy with unsealed radionuclides [R]. International Commission on Radiological Protection, Publication 94. Stockholm,Sweden:Elsevier Lid, 2004.
[10]	Larsson C M. The 2007 Recommendations of the International Commission on Radiological Protection (ICRP publication 103)[J]. Annals of the Icrp, 2007,37(2-4):1-332.
[11]	Lee J H, Park S G. Estimation of the Release Time from isolation for patients with differentiated thyroid cancer treated with high-dose I-131[J]. Nuclear Medicine & Molecular Imaging, 2010,44(4):241-245.
[12]	European Commission. Radiation protection following Iodine-131 therapy Exposures due to out patients or dis-charged in-patients[R]. Radiation Protection Report 97,1998:25.
[13]	ARPANSA. Recommendations the Discharge of Patients Undergoing Treatment with Radioactive Substances[R]. Rdiation Protection Series No.4, 2002.
[14]	中华医学会. 临床技术操作规范:核医学分册[M]. 北京:人民军医出版社, 2004.
[15]	中华人民共和国国家质量监督检验检疫总局. 电离辐射防护与辐射源安全基本标准: GB 18871—2002 [S].北京:中国标准出版化,2003.
[16]	中华人民共和国卫生部. 临床核医学放射卫生防护标准: GBZZ 120—2006 [S].北京:人民卫生出版社,2006.
[17]	中华医学会核医学分会《临床核医学辐射安全专家共识》编写委员会. 临床核医学辐射安全专家共识[J].中华核医学与分子影像杂志, 2017,37(4):225-229.
[18]	IAEA. Release of patients after radionuclide therapy[OL]. https://rpop.iaea.org/RPOP/RPoP/Content/News/release-of-patients-after-radionuclide-therapy. htm, 2015-08-24/2018-3-04
[19]	Ramírez-Garzón Y T,Ávila O, Medina L A, et al. Measurement of radiation exposure in relatives of thyroid cancer patients treated with (131)I[J]. Health Physics, 2014, 107(5):410-416.
[20]	Memon S A, Laghari N A, Qureshi S T, et al. Exposure rate patterns in (131)I therapy inpatients at NIMRA Jamshoro: an 08year study[J]. Pakistan Journal of Nuclear Medicine, 2014, 3(1):29-36.
[21]	Demir M, Parlak Y, I·ffetÇavdar, et al. The evaluation of urine activity and external dose rate from patients receiving radioiodine therapy for thyroid cancer[J]. RadiatProt Dosimetry, 2013, 156(1):25-9.
[22]	Willegaignon J, Stabin M G, Guimarães M I, et al. Evaluation of the potential absorbed doses from patients based on whole-body (131)I clearance in thyroid cancer therapy[J]. Health Physics, 2006, 91(2):123.
[23]	汤敏敏, 刘建中, 武志芳,等. 分化型甲状腺癌患者131I治疗后体内残留放射性活度的评估[J]. 中华放射医学与防护杂志, 2015, 35(4):299-302.
[24]	张海英. 放射性 (131)I治疗分化型甲状腺癌的辐射防护剂量学研究[D]. 北京协和医学院, 2015.
[25]	易艳玲. 临床核医学诊疗中的辐射剂量与防护研究[D]. 复旦大学, 2012.
[26]	Hewamanna R, Loganathan N, Perera D. Releasing thyroid cancer patients from the hospital based on dose rate measurement after 131I activity administration[J]. National Science Foundation of Sri Lanka, 2014, 42(2).
[27]	Lahfi Y, Anjak O. Measurement of the radiation dose rates of patients receiving treatment with I-131 using telescopic radiation survey meter[J]. Iranian Journal of Medical Physics, 2016, 13(1):36-42.
[28]	靳平燕. 131I治疗分化型甲状腺癌患者辐射剂量率研究[D]. 南方医科大学, 2016.
[29]	Zhang H, Jiao L, Cui S, et al. The study of external dose rate and retained body activity of patients receiving 131I therapy for differentiated thyroid carcinoma [J]. International Journal of Environmental Research & Public Health, 2014,11(10):10991.
[30]	Liu B, Peng W, Huang R, et al. Thyroid cancer: radiation safety precautions in (131)I therapy based on actual biokinetic measurements[J]. Radiology, 2014,273(1):211-219.
[31]	Kim S T, Min B, Cho J K. Analysis on distribution of effective dose rate around patients for treatment of thyroid cancer with I-131[J]. Indian Journal of Science & Technology, 2015, 8(7):533.
[32]	Tabei F, Neshandar A I, Azizmohammadi Z, et al. Assessment of radioiodine clearance in patients with differentiated thyroid cancer [J]. Radiation Protection Dosimetry, 2012, 152(4):323-7.
[33]	彭伟皑. (131)I治疗甲状腺疾病患者的外照射监测和防护[D]. 四川大学, 2006.
[34]	D'Alessio D, Giliberti C, Benassi M, et al. Potential third-party radiation exposure from patients undergoing therapy with I-131 for thyroid cancer or metastases[J]. Health Physics, 2015, 108(3):319-25.
[35]	Shah A S, Hameedullah, Farrukh S, et al. Radiation doses from iodine-131 treated hyperthyroidism patients versus life style: - A survey[J]. 2015,13(1):67-72.
[36]	Rémy H, Coulot J, Borget I, et al. Thyroid cancer patients treated with iodine-131: radiation dose to relatives after discharge from the hospital[J]. Thyroid, 2012,22(22):59-63.
[37]	Poon-iad N,Chaudakshetrin P,Sritongkul N,etal. Total effective dose equivalent to caregivers from hospitalized patients treated with high dose radioiodine for thyroid carcinoma[J]. J Med Assoc Thai, 2016; 99(2):225-30.
[38]	Khan S A, Khan M S, Arif M, et al. Radiation dose-rate reduction pattern in well-differentiated thyroid cancer treated with iodine-131 [J]. Journal of the College of Physicians and Surgeons-Pakistan:JCPSP, 2015,25(7):510.
[39]	Fatima N, Zaman M U, Zaman A, et al. Factors predicting early release of thyroid cancer patients from the isolation room after radioiodine I-131 Treatment[J]. Asian Pacific Journal of Cancer Prevention Apjcp, 2016,17(1):125.
[40]	Azizmohammadi Z, Tabei F, Shafiei B, et al. A study of the time of hospital discharge of differentiated thyroid cancer patients after receiving iodine-131 for thyroid remnant ablation treatment[J]. Hellenic Journal of Nuclear Medicine, 2013,16(2):103-106.
[41]	贺慧慧, 张敏, 郭睿,等. 甲状腺乳头状癌术后(131)I治疗的住院时间探讨[J]. 上海交通大学学报(医学版), 2015, 35(5):724-727.
[42]	Grigsby P W, Siegel B A, Baker S, et al. Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma[J]. Jama the Journal of the American Medical Association, 2000,283(17):2272.
[43]	Willegaignon J, Sapienza M, Ono C, et al. Outpatient radioiodine therapy for thyroid cancer: a safe nuclear medicine procedure[J]. Clinical Nuclear Medicine, 2011,36(6):440-445.
[44]	Kuo S F, Ho T Y, Liou M J, et al. Higher body weight and distant metastasis are associated with higher radiation exposure to the household environment from patients with thyroid cancer after radioactive iodine therapy[J]. Medicine, 2017,96(35):7942.

甲癌患者¹³¹I治疗出院标准及时间研究进展

Progress in Discharge Criteria & Time for ¹³¹I treatment of Thyroid Cancer Patients

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献 44

相关文章 1

Metrics

本文评价

推荐阅读 0